SequelSEC

Verastem, Inc. VSTM

Pharmaceutical Preparations · CIK 0001526119 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$30.91M
Fiscal year ended 2025-12-31
Operating income
-$170.13M
Fiscal year ended 2025-12-31
Free cash flow
Unavailable
Fiscal year ended 2025-12-31

Verastem, Inc. (VSTM) reported revenue of $30.91M and net income of -$209.47M for the fiscal year ended 2025-12-31. This page shows 7 annual periods of income statement, balance sheet and cash flow figures normalized from Verastem, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

Verastem, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312022-12-312021-12-312020-12-312019-12-312018-12-31
Revenue$30.91M$10.00M$2.60M$2.05M$88.52M$17.46M$26.72M
Cost of revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable$165.00K
Gross profitUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating income-$170.13M-$114.96M-$72.94M-$61.41M-$49.36M-$132.34M-$94.78M
Net income-$209.47M-$130.64M-$73.81M-$71.20M-$67.73M-$149.21M-$72.43M
Research & development$114.60M$81.33M$50.56M$39.35M$41.38M$45.78M$43.65M
Weighted-average diluted sharesshares 69.31Mshares 35.71Mshares 16.14Mshares 14.54MUnavailableshares 74.58Mshares 69.32M
Pretax income-$209.47M-$130.45M-$73.81M-$71.20M-$67.53M-$149.21M-$72.43M
Income tax expenseUnavailable$185.00K$0$0$194.00K$0$0
Diluted EPS$-3.02$-3.66$-4.57$-4.90$-0.44$-2.00$-1.37
Selling, general & administrative$81.15M$43.62M$24.98M$24.12M$62.76M$101.21M$77.26M
General & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

Verastem, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312022-12-312021-12-312020-12-312019-12-312018-12-31
Cash & equivalents$204.99M$88.82M$74.93M$21.25M$67.78M$43.51M$129.87M
Total assets$246.44M$101.54M$95.05M$108.66M$154.35M$145.05M$277.24M
Current assets$223.41M$94.96M$92.87M$105.74M$144.94M$84.96M$253.26M
Total liabilities$189.24M$130.43M$47.66M$21.10M$39.08M$137.87M$152.94M
Current liabilities$72.27M$30.97M$21.66M$18.59M$17.09M$29.89M$37.08M
Total equity incl. NCI$57.20M-$28.89M$47.39M$87.56M$115.27M$7.17M$124.30M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Inventory$1.83MUnavailableUnavailableUnavailableUnavailable$3.10M$327.00K
Accounts receivable$8.81MUnavailable$31.00K$516.00K$239.00K$2.52M$306.00K
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailable$40.72M$24.53MUnavailableUnavailable$35.10M$25.20M
Accounts payable$12.45M$4.03M$4.90M$2.30M$1.88M$9.66M$10.25M

Cash flow

Verastem, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312022-12-312021-12-312020-12-312019-12-312018-12-31
Operating cash flow-$137.51M-$104.77M-$63.67M-$53.50M-$33.51M-$138.52M-$74.52M
Capital expendituresUnavailable$28.00KUnavailable$196.00K$33.00K$7.00K$1.51M
Investing cash flow-$9.62M$59.97M$66.18M$87.00K-$47.36M$89.61M-$138.38M
Financing cash flow$263.30M$54.78M$51.78M$6.88M$69.63M-$2.44M$261.16M
Net change in cash$116.17M$9.98M$54.30M-$46.53M-$11.24M-$51.35M$48.27M
Stock-based compensation$9.40M$7.34M$6.05M$7.71M$8.12M$8.54M$6.67M
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortizationUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Derived

Verastem, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312022-12-312021-12-312020-12-312019-12-312018-12-31
Free cash flowUnavailable-$104.80MUnavailable-$53.70M-$33.54M-$138.52M-$76.02M
Gross marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating margin-550.3%-1149.6%-2809.6%-2991.2%-55.8%-758.1%-354.8%
FCF marginUnavailable-1048.0%Unavailable-2615.6%-37.9%-793.6%-284.5%
SBC / revenue30.4%73.4%232.9%375.6%9.2%48.9%25.0%
Current ratio3.09x3.07x4.29x5.69x8.48x2.84x6.83x
Revenue YoY growth209.1%Unavailable26.4%-97.7%407.1%-34.7%Unavailable
Net margin-677.6%-1306.4%-2843.3%-3468.1%-76.5%-854.8%-271.1%
R&D / revenue370.7%813.3%1947.5%1916.6%46.7%262.2%163.4%
CapEx / revenueUnavailable0.3%Unavailable9.5%0.0%0.0%5.6%
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open VSTM in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-06View SEC filing
10-Q · Filed 2026-05-07View SEC filing
10-K · Filed 2026-03-04View SEC filing
10-Q · Filed 2025-11-04View SEC filing
10-Q · Filed 2025-08-07View SEC filing
10-Q · Filed 2025-05-13View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Reconciliation checks needing review

1 period on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.

gross profit bridgeinconsistent2018-12-31

Withheld: gross profit could not be reconciled with the rest of this filer’s statement.